Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111605 · ClinicalTrials.gov registry record · Phase 1
Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
NCT00111605: Completed Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00111605 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 144 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (140% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00111605, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of an experimental HIV vaccine. The vaccine will be given with or without IL-12 DNA adjuvant (at three escalating doses of 100, 500, and 1,500 mcg respectively), a substance that helps the body respond to a vaccine. This study will also determine the safety and tolerability of an experimental HIV vaccine boosted with two adjuvants.
Interventions
- BIOLOGICAL HIV-1 gag DNA
- BIOLOGICAL HIV-1 gag DNA plus IL-12 DNA adjuvant
- BIOLOGICAL CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)
- BIOLOGICAL Sodium chloride injection (0.9%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Est. Completion | 2008-05 |
| Phase | Phase 1 |
What the finished NCT00111605 record still lists
NCT00111605 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (140% higher).
The record links to 0 conditions, and to 4 interventions - of which HIV-1 gag DNA is the first listed.
NCT00111605 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00111605 about?
NCT00111605 is a clinical study titled "Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults". The purpose of this study is to evaluate the safety and tolerability of an experimental HIV vaccine. The vaccine will be given with or without IL-12 DNA adjuvant (at three escalating doses of 100, 500, and 1,500 mcg respectively), a substance that helps the body respond to a vaccine. This study will...
What is the current status of trial NCT00111605?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 144 participants. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00111605?
The interventions under investigation include: HIV-1 gag DNA (BIOLOGICAL), HIV-1 gag DNA plus IL-12 DNA adjuvant (BIOLOGICAL), CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine) (BIOLOGICAL), Sodium chloride injection (0.9%) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00111605?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00111605's enrollment target sits among peer trials
144 394th of 2000 higher than 1,600 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS